Department of Dermatology, University of Toyama, Toyama, Japan;
Clin Cosmet Investig Dermatol. 2012;5:141-6. doi: 10.2147/CCID.S36812. Epub 2012 Sep 19.
The long-term follow-up of chronic urticaria (CU) is important to ensure the adequate treatment of patients. Olopatadine hydrochloride is one of the second-generation nonsedating antihistamines.
This study was designed to assess the optimal dose of olopatadine to suppress symptoms of chronic urticarial itch in well-controlled patients. After CU patients were treated with 10 mg olopatadine, patients having a visual analog scale (VAS) itch score of less than 20 were randomly allocated into one of three groups: 10 mg/day (n = 35), 5 mg/day (n = 30), or no medication (n = 32).
The suppressive effects of both the 5 mg and 10 mg olopatadine treatments on the VAS itch score were more significant and longer lasting over a period of 4 weeks than the no-medication treatment. Both the 5-mg group and the 10-mg group showed improved urticarial symptoms and maintained their VAS itch score within normal limits compared to the no-medication group. The differences between the 5-mg and 10-mg groups were not significant.
These results demonstrate that treatment with olopatadine at a dose of 5 mg once daily is effective and safe for the management and prevention of CU symptoms for itch in well-controlled patients.
慢性荨麻疹（CU）的长期随访对于确保患者得到充分治疗非常重要。盐酸奥洛他定是第二代非镇静抗组胺药之一。
本研究旨在评估奥洛他定的最佳剂量，以抑制控制良好的慢性荨麻疹瘙痒症状。在 CU 患者接受 10 mg 奥洛他定治疗后，视觉模拟量表（VAS）瘙痒评分小于 20 的患者被随机分为三组：10 mg/天（n=35）、5 mg/天（n=30）或不接受药物治疗（n=32）。
与不接受药物治疗相比，5 mg 和 10 mg 奥洛他定治疗在 4 周内对 VAS 瘙痒评分的抑制作用更显著且更持久。与不接受药物治疗相比，5-mg 组和 10-mg 组的荨麻疹症状均有所改善，且 VAS 瘙痒评分保持在正常范围内。5-mg 组和 10-mg 组之间的差异无统计学意义。
这些结果表明，每日一次 5 mg 奥洛他定治疗对于控制良好的患者 CU 瘙痒症状的管理和预防是有效且安全的。
